Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine

The effect of mild chronic renal failure (CRF) induced by 4/6-nephrectomy (4/6NX) on central neuronal activations was investigated by c-Fos immunohistochemistry staining and compared to sham-operated rats. In the 4/6 NX rats also the effect of the angiotensin receptor blocker, losartan, and the central sympatholyticum moxonidine was studied for two months. In serial brain sections Fos-immunoreactive neurons were localized and classified semiquantitatively. In 37 brain areas/nuclei several neurons with different functional properties were strongly affected in 4/6NX. It elicited a moderate to high Fos-activity in areas responsible for the monoaminergic innervation of the cerebral cortex, the limbic system, the thalamus and hypothalamus (e.g. noradrenergic neurons of the locus coeruleus, serotonergic neurons in dorsal raphe, histaminergic neurons in the tuberomamillary nucleus). Other monoaminergic cell groups (A5 noradrenaline, C1 adrenaline, medullary raphe serotonin neurons) and neurons in the hypothalamic paraventricular nucleus (innervating the sympathetic preganglionic neurons and affecting the peripheral sympathetic outflow) did not show Fos-activity. Stress- and pain-sensitive cortical/subcortical areas, neurons in the limbic system, the hypothalamus and the circumventricular organs were also affected by 4/6NX. Administration of losartan and more strongly moxonidine modulated most effects and particularly inhibited Fos-activity in locus coeruleus neurons. In conclusion, 4/6NX elicits high activity in central sympathetic, stress- and pain-related brain areas as well as in the limbic system, which can be ameliorated by losartan and particularly by moxonidine. These changes indicate a high sensitivity of CNS in initial stages of CKD which could be causative in clinical disturbances.

[1]  M. Selley Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease , 2003, Neurobiology of Aging.

[2]  D. Tanné,et al.  Kidney function is associated with the rate of cognitive decline in the elderly , 2009, Neurology.

[3]  E. Timofeeva,et al.  Activation of the central nervous system in obese Zucker rats during food deprivation , 2001, The Journal of comparative neurology.

[4]  H. Haas,et al.  The role of histamine and the tuberomamillary nucleus in the nervous system , 2003, Nature Reviews Neuroscience.

[5]  M. Bossola,et al.  Anorexia in hemodialysis patients: an update. , 2006, Kidney international.

[6]  V. Campese,et al.  Losartan Reduces Central and Peripheral Sympathetic Nerve Activity in a Rat Model of Neurogenic Hypertension , 2002, Hypertension.

[7]  R. Selgas,et al.  Uremic Anorexia: A Consequence of Persistently High Brain Serotonin Levels? The Tryptophan/Serotonin Disorder Hypothesis , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[8]  D. Holland,et al.  Quality of sleep in patients with chronic kidney disease. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  J. Fischer,et al.  Blood-brain barrier derangement in uremic encephalopathy. , 1982, Surgery.

[10]  M. Goicochea,et al.  Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. , 2008, Kidney international. Supplement.

[11]  P. Kotanko Cause and Consequences of Sympathetic Hyperactivity in Chronic Kidney Disease , 2005, Blood Purification.

[12]  A. Blomqvist,et al.  Forebrain patterns of c‐Fos and FosB induction during cancer‐associated anorexia–cachexia in rat , 2005, The European journal of neuroscience.

[13]  Scott D. Cohen,et al.  Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[14]  P. Jungers,et al.  Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. , 1998, Journal of immunology.

[15]  J. Gutkowska,et al.  Atrial natriuretic peptide is involved in renal actions of moxonidine. , 2000, Hypertension.

[16]  T. Çaycı,et al.  Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  E. Ritz,et al.  Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. , 2000, Journal of the American Society of Nephrology : JASN.

[18]  D. Knopman,et al.  Cognitive impairment in hemodialysis patients is common , 2006, Neurology.

[19]  M. Palkovits,et al.  Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain. , 2001, Pharmacological research.

[20]  P. Wolf,et al.  Association of Plasma ADMA Levels With MRI Markers of Vascular Brain Injury: Framingham Offspring Study , 2009, Stroke.

[21]  G. Mancia,et al.  Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[22]  Frank Donnerstag,et al.  ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans , 2006, Stroke.

[23]  T. Herdegen,et al.  Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins , 1998, Brain Research Reviews.

[24]  P. Kimmel,et al.  The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. , 2006, Kidney international.

[25]  R. Converse,et al.  Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.

[26]  R. Bigazzi,et al.  Altered norepinephrine turnover in the brain of rats with chronic renal failure. , 1994, Journal of the American Society of Nephrology : JASN.

[27]  P. Boor,et al.  Neuronal activation in the CNS during different forms of acute renal failure in rats , 2009, Neuroscience.

[28]  A. Heidland,et al.  Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan , 1999, Mineral and Electrolyte Metabolism.

[29]  P. Riederer,et al.  Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress , 1998, Journal of Neural Transmission.

[30]  K. Kelly Distant effects of experimental renal ischemia/reperfusion injury. , 2003, Journal of the American Society of Nephrology : JASN.

[31]  F. Kronenberg,et al.  Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[32]  D. Reaich Odour perception in chronic renal disease , 1997, The Lancet.

[33]  M. Palkovits,et al.  Atrial Natriuretic Peptide in Brain Preoptic Areas: Implications for Fluid and Salt Homeostasis , 1988, Journal of cardiovascular pharmacology.

[34]  Mark McEvoy,et al.  Asymmetric dimethylarginine: a possible link between vascular disease and dementia. , 2013, Current Alzheimer research.

[35]  F. Dekker,et al.  The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  M. Zeier,et al.  Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  C. Abbadie,et al.  c-fos Expression in rat lumbar spinal cord during the development of adjuvant-induced arthritis , 1992, Neuroscience.

[38]  M. Samuels,et al.  Uremic encephalopathy and other brain disorders associated with renal failure. , 2011, Seminars in neurology.

[39]  E. Senba,et al.  Stress-induced hyperalgesia: animal models and putative mechanisms. , 2006, Frontiers in bioscience : a journal and virtual library.

[40]  P. Blankestijn,et al.  Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. , 2004, Kidney international.

[41]  E. Sabban,et al.  Single and repeated immobilization stress differentially trigger induction and phosphorylation of several transcription factors and mitogen‐activated protein kinases in the rat locus coeruleus , 2005, Journal of neurochemistry.

[42]  J. Fischer,et al.  Blood-brain barrier derangement in sepsis: cause of septic encephalopathy? , 1981, American journal of surgery.

[43]  D. Averill,et al.  Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II andL-glutamate in rostral ventrolateral medulla , 1994, Brain Research.

[44]  B. Prichard,et al.  Moxonidine: a new antiadrenergic antihypertensive agent. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[45]  S. Yusuf,et al.  Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. , 2011, Archives of internal medicine.

[46]  K. Jellinger,et al.  Brain monoamines in metabolic (endotoxic) coma a preliminary biochemical study in human postmortem material , 2005, Journal of Neural Transmission.

[47]  S. Waldstein,et al.  Renal Function and Cardiovascular Response to Mental Stress , 2007, American Journal of Nephrology.

[48]  M. Palkovits,et al.  Effect of ACE inhibitors on atrial natriuretic factor in the brains of rats with reduced renal mass. , 1993, Kidney international.

[49]  E. Ritz,et al.  Sympathetic overactivity and arterial hypertension in renal failure. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  M. Neil,et al.  Clonidine: clinical pharmacology and therapeutic use in pain management. , 2011, Current clinical pharmacology.

[51]  B. Landis,et al.  Olfactory function improves following hemodialysis. , 2011, Kidney international.

[52]  D. G. Laing,et al.  Smell and taste function in children with chronic kidney disease , 2010, Pediatric Nephrology.

[53]  H. Przuntek,et al.  Increased histidine and histamine content in the brain of chronic uremic rats. Cause of enhanced cerebral cyclic adenosine monophosphate in uremia? , 1978, The American journal of clinical nutrition.

[54]  P. D. De Deyn,et al.  Marconi revisited: from kidney to brain--two organ systems communicating at long distance. , 2008, Journal of the American Society of Nephrology : JASN.

[55]  E. Miller,et al.  An integrative theory of prefrontal cortex function. , 2001, Annual review of neuroscience.

[56]  J. Williamson,et al.  Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. , 2009, Archives of internal medicine.

[57]  T. Hostetter,et al.  Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). , 2007, Journal of the American Society of Nephrology : JASN.

[58]  B. Spiegel,et al.  Biomarkers and health-related quality of life in end-stage renal disease: a systematic review. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[59]  I. Liu,et al.  Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. , 2009, Chest.

[60]  H. Critchley,et al.  Brain systems for baroreflex suppression during stress in humans , 2012, Human brain mapping.

[61]  S. Kuroda,et al.  Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species , 2006, Brain Research.

[62]  V. Campese,et al.  Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. , 1997, Kidney international.

[63]  S. Tufik,et al.  Genomic damage in the progression of chronic kidney disease in rats , 2011, Brain, Behavior, and Immunity.

[64]  P. Blankestijn,et al.  J Am Soc Nephrol 15: 524–537, 2004 Sympathetic Hyperactivity in Chronic Renal Failure: A Wakeup , 2022 .

[65]  V. Wadley,et al.  Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[66]  A. Bomback,et al.  Olfactory function in dialysis patients: a potential key to understanding the uremic state. , 2011, Kidney international.

[67]  R. Casper,et al.  Depression and eating disorders , 1998, Depression and anxiety.

[68]  V. Campese,et al.  Losartan reduces sympathetic nerve outflow from the brain of rats with chronic renal failure , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[69]  A. Morrison Experimentally induced chronic renal insufficiency in the rat. , 1962, Laboratory investigation; a journal of technical methods and pathology.

[70]  J. Stamp,et al.  Multiple immediate-early gene expression during physiological and endocrine adaptation to repeated stress , 1999, Neuroscience.

[71]  P. Riederer,et al.  Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[72]  A. Abdelhafiz,et al.  Microalbuminuria: Marker or Maker of Cardiovascular Disease , 2011, Nephron Experimental Nephrology.

[73]  S. Seliger,et al.  Chronic kidney disease, creatinine and cognitive functioning. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[74]  Eduardo E. Benarroch,et al.  The locus ceruleus norepinephrine system , 2009, Neurology.

[75]  D. Morgan,et al.  L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[76]  Giuseppe Mancia,et al.  Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure , 2011, Hypertension.

[77]  P. Deyn,et al.  Neurological complications in renal failure: a review , 2004, Clinical Neurology and Neurosurgery.

[78]  V. Campese,et al.  Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. , 2004, American journal of physiology. Heart and circulatory physiology.

[79]  Paul J Thornalley,et al.  Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. , 2007, Kidney international.

[80]  F. Grodstein,et al.  Kidney dysfunction and cognitive decline in women. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[81]  T. Singer,et al.  The neural basis of empathy. , 2012, Annual review of neuroscience.

[82]  K. Parker Sleep disturbances in dialysis patients. , 2003, Sleep medicine reviews.

[83]  S. Davison Chronic pain in end-stage renal disease. , 2005, Advances in chronic kidney disease.

[84]  L. Price,et al.  Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[85]  T. Curran,et al.  Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. , 1991, Annual review of neuroscience.

[86]  D. Knopman Invited commentary: Albuminuria and microvascular disease of the brain--a shared pathophysiology. , 2010, American journal of epidemiology.

[87]  A. Grandi,et al.  Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade , 2002, Journal of hypertension.

[88]  G. Fink,et al.  Differential activation of memory-relevant brain regions during a dialysis cycle. , 2010, Kidney international.

[89]  J. Slaets,et al.  Association of cognitive function with albuminuria and eGFR in the general population. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[90]  P. Ernsberger,et al.  Pharmacology of moxonidine, an I1-imidazoline receptor agonist. , 1996, Journal of cardiovascular pharmacology.

[91]  Takeo Kato,et al.  Cerebral small vessel disease and chronic kidney disease (CKD): Results of a cross-sectional study in community-based Japanese elderly , 2008, Journal of the Neurological Sciences.

[92]  R. Vanholder,et al.  What is new in uremic toxicity? , 2008, Pediatric Nephrology.

[93]  I. Reid Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. , 1992, The American journal of physiology.

[94]  Morrison Ab Experimentally induced chronic renal insufficiency in the rat. , 1962 .

[95]  M. Cirillo,et al.  A longitudinal study of sleep disorders in early-stage chronic kidney disease. , 2010, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[96]  M. Koss,et al.  Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[97]  M. Swendseid,et al.  Brain serotonin turnover in chronically uremic rats. , 1977, The American journal of physiology.

[98]  P. Ernsberger,et al.  Pharmacology of Moxonidine, an I1‐Imidazoline Receptor Agonist , 2000, Journal of cardiovascular pharmacology.